MECP2 and juvenile Huntington disease: It is reported that, in animal models of Rett syndrome (RTT), a neurodevelopmental disorder mostly due to mutations in the X-linked transcriptional regulator methyl CpG binding protein 2 (MeCP2), symptoms can be improved or prevented by re-expression of MeCP2 merely in astrocytes [179] What is more, the glia cells also have a strong impact in Huntington’s disease (HD), a neuronal disease usually associated with neuronal dysfunction and atrophy of the striatum and other brain areas.